Lack of peroxisome proliferator-activated receptor α in mice enhances methionine and choline deficient diet-induced steatohepatitis

Hepatology Research

Volumn 30, Issue 2, 2004, Pages 104-110

  Kashireddy, Papreddy V ^a   Rao, M Sambasiva ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatocyte proliferation; Long chain fatty acids; PCNA; Serum enzymes; Steatosis; Triglycerides; oxidation of fatty acids

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINE; METHIONINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DIET; DISEASE SEVERITY; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; HEPATITIS; LIVER CELL; LIVER HYPERPLASIA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN DEFICIENCY; WILD TYPE;

EID: 4644370807     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2004.06.004     Document Type: Article

References (40)

1. Rao MS, Reddy JK. Peroxisomal β-oxidation and steatohepatitis. Sem Liver Dis 2001;21:43-54.
2. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem 1998;273:5678-84.
3. Yeldandi AV, Rao MS, Reddy JK. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mut Res 2000;448:159-77.
4. Green S, Wahli W. Peroxisome proliferator-activated receptors. Finding the orphan a home. Mol Cell Endocrinol 1994;100:149-53.
5. Lemberger T, Braissant O, Juge-Aubry C, et al. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann NY Acad Sci 1996:231-51.
6. Reddy JK, Lalwani ND. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit Rev Toxicol 1983;12:1-58.
7. Cohen AJ, Grasso P. Review of the hepatic response to hypolipidemic drugs in rodents and assessment of its toxicological significance to man. Fd Cosmet Toxicol 1981;19:585-605.
8. Yu S, Rao MS, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Cur Mol Med 2003;3:561-72.
9. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the α isoform of the peroxisome proliferation-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
10. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000;275:28918-28.
11. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest 1999;103:1489-98.
12. Peters JM, Cattley RC, Gonzalez FJ. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14, 643. Carcinogenesis 1997;18:2029-33.
13. Dianzani MU. Biochemical aspects of fatty liver. In: Meeks RG, Harrison SD, Bull RJ, editors. Hepatotoxicology. Boca Raton: CRC Press; 1991. p. 327-99.
14. Day CP, James OFW. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-5.
15. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Sem Diag Pathol 1998;15:246-58.
16. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
17. Ghoshal AK, Farber E. Choline deficiency, lipotrope deficiency and the development of liver disease including liver cancer: a new perspective. Lab Invest 1993;68:255-60.
18. Rao MS, Kashireddy P, Musunuri S, Okonkwo A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator activated receptor α ligand in rats. In Vivo 2002;16:145-52.
19. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000;105:1067-75.
20. Kashireddy PV, Rao MS. Sex differences in choline deficient diet-induced steatohepatitis in mice. Exp Biol Med 2004;229:158-62.
21. Leiber C. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol 2000;32(Suppl 1):113-28.
22. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Sem Liver Dis 2001;21:27-41.
23. Olivera CP, da costa Gayotto LC, Tatai C, et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed a choline deficient diet. J Cell Mol Med 2002;6:399-406.
24. Abanobi SE, Lombardi B, Shinozuka H. Stimulation of DNA synthesis and cell proliferation in the liver of rats fed a choline-devoid diet and their suppression by Phenobarbital. Cancer Res 1982;42:412-5.
25. Chandar N, Amenta J, Kandala JC, Lombardi B. Liver cell turnover in rats fed a choline-devoid diet. Carcinogenesis 1987;8:669-73.
26. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
27. Muskhelishvili L, Latendresse JR, Kodell RL, Henderson EB. Evaluation of cell proliferation in rat tissues with BrdU, PCNA Ki-67 (MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem 2003;51: 1681-8.
28. Columbano A, Ledda-Columbano GM, Pibiri M, et al. Peroxisome proliferator-activated receptor-α-/- mice show enhanced hepatocyte proliferation in response to the hepatomitogen 1,4-bis[2-(3,5-dichloropyridoxy)] benzene, a ligand of constitutive androstane receptor. Hepatology 2001;34:262-6.
29. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003;38:123-32.
30. Yin M, Ikejima K, Wheeler MD, et al. Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model. Hepatology 2000;31:117-23.
31. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3-10.
32. Hashimoto T, Fujita T, Usuda N, et al. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1999;274:19228-36.
33. Koteish A, Diehl AM. Animal models of steatosis. Sem Liver Dis 2001;21:89-104.
34. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999:1634-6.
35. Zafrani ES. Nonalcoholic fatty liver disease: an emerging pathophysiological spectrum. Virch Arch 2004;444:3-12.
36. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
37. Columbano A, Shinozuka H. Liver regeneration versus direct hyperplasia. FASEB J 1996;10:1118-28.
38. Rao MS, Peters JM, Gonzalez FK, Reddy JK. Hepatic regeneration in peroxisome proliferator-activated receptor α-null mice after partial hepatectomy. Hep Res 2002;22:52-7.
39. Goshal AK, Ahluwalia M, Farber E. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am J Pathol 1983;113:309-14.
40. Eldridge SR, Butterworth BE, Goldsworthy TL. Proliferating cell nuclear antigen: a marker for hepatocellular proliferation in rodents. Environ Health Perspect 1993;101(sup.5):211-8.